Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. (NYSE American: ELMD) is a medical device company that develops, manufactures, and sells airway clearance therapy products, including the SmartVest® Airway Clearance System, for patients with compromised pulmonary function. Company news often highlights its role as a leader in airway clearance technologies and its focus on High Frequency Chest Wall Oscillation (HFCWO) therapy, particularly in the homecare setting.
Newsflow for Electromed frequently centers on financial results, such as quarterly and annual earnings releases that detail net revenues, operating income, net income, and segment performance in direct homecare and non-homecare markets. These announcements often discuss trends in referrals and approvals, sales force expansion, and gross margin dynamics, as well as commentary from management on operational execution and efficiency initiatives.
Investors can also expect corporate and capital markets updates, including announcements about share repurchase authorizations approved by the board of directors and index-related milestones, such as Electromed’s addition to the Russell 2000® and Russell 3000® indexes. The company issues press releases when it schedules earnings conference calls and webcasts, providing dial-in details and replay information.
Another recurring category of news involves investor conference participation. Electromed regularly announces its presence at events hosted by organizations such as Noble Capital Markets, LD Micro, Canaccord Genuity, and Investor Summit, where management presents the company’s airway clearance business and growth strategy to institutional and other investors.
For readers tracking ELMD, this news page provides a centralized view of Electromed’s earnings announcements, capital allocation decisions, index inclusions, and investor outreach activities, offering context on how the company is executing its strategy in the airway clearance therapy market.
Electromed, Inc. (NYSE: ELMD) has announced a cooperation agreement with Summers Value Partners, which holds 5.9% of its stock, leading to the nomination of two new independent directors, Kathy Tune and Joe Galatowitsch, for the upcoming Fiscal 2022 Annual Meeting. A new Finance and Strategy Committee will be formed to enhance value creation. Retiring board members Steve Craney and George Winn will leave their positions. The company highlighted its commitment to growth, showcasing a strategy that aims for double-digit revenue growth and profitability.
Electromed, Inc. (AMEX: ELMD) has announced that its President and CEO, Kathleen Skarvan, along with CFO Mike MacCourt, will participate in the 2021 Colliers Institutional Investor Conference on September 9, 2021. The conference will be held virtually, highlighting the company’s commitment to engaging with investors and stakeholders. Electromed specializes in airway clearance technologies, notably the SmartVest® Airway Clearance System, to assist patients with compromised pulmonary function. The company is based in New Prague, Minnesota, and has been operational since 1992.
Electromed reported strong Q4 FY 2021 results, with a net revenue increase of 37.7% to $9.5 million, driven by a 90.6% growth in institutional sales and 33.6% in home care. Despite revenue growth, operating income fell to $0.7 million from $1.3 million in Q4 FY 2020, affected by past government stimulus and increased SG&A expenses. For FY 2021, total revenue rose 10.1% to $35.8 million but net income declined to $2.4 million, or $0.27 per diluted share. Cash reserves were $11.9 million, bolstered by $3.1 million in operating cash flow.
Electromed (NYSE American: ELMD) announced that it will release its fiscal 2021 fourth quarter financial results on August 24, 2021, post-market close. A conference call will follow at 5:00 PM ET to discuss the results. Participants can join via domestic and international dialing or through a live webcast available on the Investor Relations section of their website. The company specializes in airway clearance therapy products, including the SmartVest Airway Clearance System, supporting patients with compromised pulmonary function.
Electromed (NYSE American: ELMD) announced that Summers Value Partners intends to nominate four candidates for election to the Board of Directors at the upcoming Fiscal 2022 Annual Meeting of Shareholders. The Board is currently engaged in discussions with Summers Value Partners to evaluate the nominees, focusing on shareholder interests. With insiders owning over 16% of Electromed's shares, their interests align closely with those of the shareholders. A proxy statement detailing the Board's recommendations will be filed with the SEC and distributed to eligible shareholders.
Electromed, Inc. (NYSE American: ELMD) announced preliminary Q4 FY 2021 financial results, projecting net revenue of $9.3 to $9.5 million, a 37% increase from $6.9 million in Q4 FY 2020. Operating income is expected to be between $0.5 and $0.7 million, down from $1.3 million the previous year, which included $0.9 million from government stimulus. The company reported $11.9 million in cash with no debt. Management indicated that a recent data security incident did not materially impact financial results for the quarter, affirming strong performance despite pandemic challenges.
Electromed, a leader in airway clearance technologies (NYSE American: ELMD), announced participation in Canaccord Genuity’s 41st Annual Growth Conference, scheduled for August 10-12, 2021. The group presentation will take place on August 11, 2021, at 10:00 AM Eastern Time. Attendees can access the webcast through a link provided in the press release or via the Investor Relations section of Electromed’s website. The company specializes in airway clearance therapy products, including the SmartVest Airway Clearance System, and was founded in 1992 and is headquartered in New Prague, Minnesota.
Electromed, Inc. (NYSE American: ELMD) has announced a $3.0 million stock repurchase authorization effective May 26, 2021. The company plans to buy back its common stock, with purchases made in open market transactions or through block trades. This move is driven by a strong balance sheet and positive cash flow, reflecting management's belief that the stock is undervalued. The buyback program is set to continue until May 26, 2022, but may be modified or discontinued at any time.
Electromed, Inc. (NYSE American: ELMD) has been recognized as Quality Magazine’s 2021 Plant of the Year. This accolade is based on the 2021 Quality Leadership Top 100 Company survey, which evaluates continuous improvement, quality training, warranty costs, and ISO certifications, including ISO 13485. Electromed has ranked among the top 10 in this survey three times in the last four years. CEO Kathleen Skarvan emphasized the recognition reflects the team's dedication to improving patient lives through high-quality products and services.
Electromed, Inc. (NYSE American: ELMD) reported its Q3 FY 2021 financial results, revealing a 0.5% increase in net revenue to $8.8 million, driven by a 4.2% rise in home care revenue. The gross profit percentage improved to 76.3% of net revenue. However, net income fell to $224,000 or $0.03 per diluted share, down from $653,000 or $0.07 in Q3 FY 2020, mainly due to increased investments in R&D and SG&A. Cash at March 31, 2021 stood at $12.5 million, supported by $834,000 in operating cash flow. Despite challenges from COVID-19, management expressed optimism for ongoing recovery.